Abstract: Apelin receptor modulators can improve physical performance, slow progression of age-related frailty, and can reduce age-related muscle weakness in human patients. This disclosure provides methods for treating muscle conditions using a particular class of apelin receptor modulators (e.g., agonists). The muscle condition can be an age-related muscle condition. Also provided is a method for maintaining and/or increasing muscle mass, muscle function, and/or muscle strength in an elderly subject by administration of the apelin receptor modulator. In some embodiments, the apelin receptor modulator (e.g., agonist) is BGE-105, or a pharmaceutically acceptable salt thereof.

Abstract: This disclosure provides methods for using a particular class of apelin receptor modulators to reduce blood-brain barrier (BBB) permeability in a subject in need thereof, and in particular methods of treatment for a variety of disorders, conditions, and diseases associated with and related to increased BBB permeability. This disclosure also provides methods for using a particular class of apelin receptor modulators to treat a neurodegenerative disease, delirium, and/or dementia in a subject in need thereof. This disclosure also provides methods for using a particular class of apelin receptor modulators to reduce neuroinflammation in a subject in need thereof. In some embodiments, the apelin receptor modulator (e.g., agonist) is BGE-105, or a pharmaceutically acceptable salt thereof.

Abstract: The present disclosure provides a method of treating a condition associated with aging, including a disease or condition selected from anemia, including unexplained anemia of the elderly, spontaneous anemia of aging, and anemia of inflammation in the elderly, sarcopenia, frailty, tissue injury, muscle injury, and ischemic damage, the method comprising administering to an elderly subject a therapeutically effective amount of a hypoxia-inducible factor prolyl hydroxylase inhibitor.

Abstract: Systems, methods, and non-transitory computer-readable storage media for gathering activity data describing a user's activities from one or more activity sensors and using the activity data to predict immune-response to the activity. Predicting immune-response can involve creating, personalizing, and refining immune-response prediction models based on demographic user data, activity data, blood sample data, personal genetic information.

Abstract: Systems, methods, and non-transitory computer-readable storage media for gathering activity data describing a user's activities from one or more activity sensors and using the activity data to predict immune-response to the activity. Predicting immune-response can involve creating, personalizing, and refining immune-response prediction models based on demographic user data, activity data, blood sample data, personal genetic information.

Abstract: Systems, methods, and non-transitory computer-readable storage media for gathering activity data describing a user's activities from one or more activity sensors and using the activity data to predict immune-response to the activity. Predicting immune-response can involve creating, personalizing, and refining immune-response prediction models based on demographic user data, activity data, blood sample data, personal genetic information.

Abstract: Systems, methods, and non-transitory computer-readable storage media for constructing a clinically-derived and personalized blood cell mobilization prediction models, enhancing the understanding of a blood tests by excluding the contemporary effect of the contemporary activity from the contemporary blood sample data, optimizing a vaccine by maximizing a concentration of a collection of immune cells which interact with the collection of antigens present in the vaccine can be prescribed, and enhancing the reliability of activity data by accounting for inconsistencies, gaps in data, etc. that is collected from telemetric devices.

Abstract: A major type of unwanted cells that accumulate in aging are anergic cytotoxic T-cells. These cells often have virus-specific T-cell receptors, as well as other surface markers that distinguish them from their youthful counterparts, and are thought to play a major role in the decline of the immune system with age. Here we disclose the use of magnetic cell separation methods and apparatuses to remove senescent T-cells defined by the surface markers CD8+, KLRG1+ and CD8+, CD28?. We disclose how these markers are used to remove anergic T-cells from the blood of aged C57BL/6 mice, resulting in lasting rejuvenation of their immunological marker profile. Using antibodies with magnetic microparticles linked to their Fc domains, we first developed a method to use magnets to filter out the unwanted cells from the blood, and later constructed a device that does this automatically.